<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               12 CLINICAL PHARMACOLOGY<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        12.1 Mechanism of Action<BR>                     <BR>                     <BR>                        The mechanism of action of carisoprodol in relieving discomfort associated with acute painful musculoskeletal conditions has not been clearly identified.<BR>                        In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        12.2 Pharmacodynamics<BR>                     <BR>                     <BR>                        Carisoprodol is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscles.  <BR>                        A metabolite of carisoprodol, meprobamate, has anxiolytic and sedative properties.  The degree to which these properties of meprobamate contribute to the safety and efficacy of Carisoprodol Tablets is unknown.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        12.3 Pharmacokinetics<BR>                     <BR>                     <BR>                        The pharmacokinetics of carisoprodol and its metabolite meprobamate were studied in a crossover study of 24 healthy subjects (12 male and 12 female) who received single doses of 350 mg Carisoprodol Tablets (see Table 2). The Cmax of meprobamate was 2.5 ± 0.5 µg/mL (mean ± SD) after administration of a single 350 mg dose of Carisoprodol Tablets, which is approximately 30% of the Cmax of meprobamate (approximately 8 µg/mL) after administration of a single 400 mg dose of meprobamate.<BR>                        <BR>                           Table 2. Pharmacokinetic Parameters of Carisoprodol and Meprobamate (Mean ± SD, n=24)<BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" colspan="3">&#160;</td><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td/><BR>                                 <td align="center">&#160; </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">350 mg Carisoprodol Tablets</content>&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" colspan="5">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" colspan="5"><BR>                                    <content styleCode="bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carisoprodol</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">C<sub>max</sub>(&#181;g/mL)</content><BR>                                 </td><BR>                                 <td align="center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td><BR>                                 <td align="center"/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">1.8 &#177; 1.0&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">AUC<sub>inf</sub> (&#181;g*hr/mL)</content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">7.0 &#177; 5.0&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">T<sub>max</sub> (hr)</content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">&#160;1.7 &#177; 0.8</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">T<sub>1/2</sub> (hr) </content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">&#160;2.0 &#177; 0.5</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" colspan="5"><BR>                                    <content styleCode="bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Meprobamate</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">C<sub>max</sub>(&#181;g/mL) </content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">2.5 &#177; 0.5&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">AUC<sub>inf </sub>(&#181;g*hr/mL)</content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">&#160;46 &#177; 9.0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">T<sub>max</sub> (hr)</content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">4.5 &#177; 1.9&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">T<sub>1/2</sub> (hr) </content><BR>                                 </td><BR>                                 <td align="center"/><BR>                                 <td/><BR>                                 <td align="center">&#160;</td><BR>                                 <td align="center">&#160;9.6 &#177; 1.5</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" colspan="3"/><BR>                                 <td>&#160;</td><BR>                                 <td align="center">&#160;</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Absorption:  Absolute bioavailability of carisoprodol has not been determined.  The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.  Co-administration of a high-fat meal with Carisoprodol Tablets (350 mg tablet) had no effect on the pharmacokinetics of carisoprodol.  Therefore, Carisoprodol Tablets may be administered with or without food.<BR>                        <BR>                           Metabolism:  The major pathway of carisoprodol metabolism is via the liver by cytochrome enzyme CYP2C19 to form meprobamate.  This enzyme exhibits genetic polymorphism (see Patients with Reduced CYP2C19 Activity below).<BR>                        <BR>                           Elimination:  Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.  The half-life of meprobamate is approximately 10 hours.<BR>                        <BR>                           Gender:  Exposure of carisoprodol is higher in female than in male subjects (approximately 30-50% on a weight adjusted basis).  Overall exposure of meprobamate is comparable between female and male subjects.<BR>                        <BR>                           Patients with Reduced CYP2C19 Activity:  Carisoprodol Tablets should be used with caution in patients with reduced CYP2C19 activity.  Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and concomitant 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers.  The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3 - 5% and in Asians is approximately 15 - 20%.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>